What You Should Know:
– HeartBeam, a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a strategic collaboration with AccurKardia, an innovator in ECG-based diagnostics technology.
– The partnership unites two innovation leaders in ambulatory electrocardiogram (ECG) recording and analysis, aiming to enhance the accessibility of advanced cardiac monitoring solutions.
Integrating Advanced ECG Analysis Capabilities
The initial phase of the collaboration will focus on making AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, available on HeartBeam’s proprietary monitoring devices*. AccurECG™ is a device-agnostic platform designed to provide automated interpretation of ECG data, offering valuable insights for clinical assessment.
Enhancing Future Arrhythmia Assessment Offerings
By incorporating AccurKardia’s automated interpretation capabilities, HeartBeam intends to bolster its subsequent commercial product offerings, specifically those focused on arrhythmia assessment. The integration aims to enable patients and their physicians to receive an automated rhythm assessment via the HeartBeam system. This feature is expected to facilitate quicker diagnoses of potential heart rhythm issues and enable faster access to appropriate clinical care when needed.
“We believe combining AccurKardia’s device-agnostic, FDA-cleared automated ECG analytics with HeartBeam’s novel credit card-sized device will be a true game-changer that empowers patients to take charge of their cardiac health, wherever they are. By uniting our strengths, we’re creating a best-in-class platform that transforms how cardiac arrhythmia conditions are monitored and detected,” said Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia. “Putting clinical-grade ECG insights directly into a patient’s pocket aims to meaningfully address the increasing lack of access to cardiology specialists in the United States.”
